Sponsor Partnerships
MedPoint Research Institute is a high-performance clinical research site built to support sponsors and CROs with efficient, reliable, and compliant study execution.
Clinical Capabilities
Med Point Research Institute is equipped with purpose-built infrastructure designed to support complex clinical trial execution and full regulatory compliance, including:
Multiple fully equipped clinical examination rooms optimized for efficient patient flow.
Temperature-controlled storage systems (-80°C, -20°C, and 2–8°C) for specimens and investigational products.
Dedicated infusion and procedure spaces designed for safety, precision, and patient comfort.
On-site ECG and diagnostic monitoring capabilities.
Secure, GxP-compliant investigational product storage with controlled access systems.
Refrigerated centrifugation and sample processing capabilities.
Structured regulatory documentation and archival systems.
Dedicated monitoring and sponsor visit workspace to support audits and oversight activities.
Administrative and operational offices designed to support high-volume clinical trial execution.
At Med Point Research Institute, we understand that successful clinical trials depend on execution as much as infrastructure. Our team is committed to proactive communication, strict regulatory adherence, timely data management, and close collaboration with sponsors and CRO partners.
We aim to function as a true extension of your clinical development team—focused on delivering reliable enrollment, operational efficiency, and high-quality clinical outcomes.
Why Partner With MedPoint
We deliver operational excellence through:
Fast study startup timelines
High-quality patient recruitment
Strong retention strategies
Experienced clinical research team
Diverse South Texas population access
GCP-compliant operations
Our Advantage
Community-driven recruitment network
Bilingual participant engagement
Efficient site coordination
Scalable enrollment capacity
Strong physician and referral relationships
Ideal Studies
We support Phase II–IV clinical trials across: